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Abstract
Purpose
Unambiguous evaluation of glioblastoma (GB) progression is crucial, both for clinical trials
as well as day by day routine management of GB patients. 3D-volumetry in the follow-up of
GB provides quantitative data on tumor extent and growth, and therefore has the potential
to facilitate objective disease assessment. The present study investigated the utility of abso-
lute changes in volume (delta) or regional, segmentation-based subtractions for detecting
disease progression in longitudinal MRI follow-ups.
Methods
165 high resolution 3-Tesla MRIs of 30 GB patients (23m, mean age 60.2y) were retrospec-
tively included in this single center study. Contrast enhancement (CV) and tumor-related
signal alterations in FLAIR images (FV) were semi-automatically segmented. Delta volume
(dCV, dFV) and regional subtractions (sCV, sFV) were calculated. Disease progression was
classified for every follow-up according to histopathologic results, decisions of the local mul-
tidisciplinary CNS tumor board and a consensus rating of the neuro-radiologic report.
Results
A generalized logistic mixed model for disease progression (yes / no) with dCV, dFV, sCV
and sFV as input variables revealed that only dCV was significantly associated with predic-
tion of disease progression (P = .005). Delta volume had a better accuracy than regional,
segmentation-based subtractions (79% versus 72%) and a higher area under the curve by
trend in ROC curves (.83 versus .75).
Conclusion
Absolute volume changes of the contrast enhancing tumor part were the most accurate vol-
umetric determinant to detect progressive disease in assessment of GB and outweighed
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FLAIR changes as well as regional, segmentation-based image subtractions. This parame-
ter might be useful in upcoming objective response criteria for glioblastoma.
Introduction
MR imaging plays a central role in response assessment of glioblastoma (GB), both in clinical
trials as well as in the daily clinical management of GB patients. To avoid inter-observer bias of
visual image interpretation, means to provide a more objective imaging assessment by quanti-
fying image information like GB growth are receiving increasing attention [1–4]. Many efforts
have been made to reliably quantify glioblastomas in MR images [2–18]. Response evaluation
criteria in solid tumors (RECIST), Macdonald criteria or response assessment in neuro-oncol-
ogy working group (RANO) criteria apply one- or two-dimensional assessments such as lon-
gest tumor diameter or the products of perpendicular diameters respectively [2–4]. Even
though RANO criteria are broadly and easily applicable and help to standardize response eval-
uation, reproducibility is low and there are several limitations, especially for irregular-shaped
tumors or masses around resection cavities or cysts [4,19].
Three-dimensional volumetric tumor assessment using MR image segmentations might
overcome current limitations of uni- and biplanar assessments and offers an elegant way to
quantify image information [5,6,8,18]. There is a strong need and a high interest in reliable
image segmentation techniques, which gets mirrored in the exponential rise of studies on
image segmentation [5]. In general, three different segmentation techniques are widely
applied: manual, semi-automated and fully automated segmentation techniques. Manual seg-
mentations are still regarded as the gold standard in many imaging studies but require a
human rater which makes them often time consuming and prone to bias [18]. Semi-automated
segmentation tools often apply intelligent region-growing algorithms that assist the rater dur-
ing the delineation, saving time and increasing homogeneity of segmentations [13–
15,18,20,21]. Automated segmentation techniques offer constant results but still have several
limitations in terms of precision or unexpected signal alterations like in postoperative MRI of
GB [5,6,16,17,22].
Contrast enhanced T1-weighted and T2-weighted fluid-attenuated-inversion-recovery
(FLAIR) sequences are crucial for glioma evaluation and are consequently part of a consensus
recommendation for respective imaging protocols [23]. With modern segmentation tech-
niques being widely-used, quantification of tumor volume is now feasible in MRI follow-ups
with only moderate effort. Even though reliable segmentation techniques are progressively
studied and volumetric assessments are increasingly applied in new imaging studies [6–8],
their diagnostic benefit still remains uncertain [5,11,12]. Further it is not clear which volumet-
ric determinant should be addressed in the follow-up of GB since many studies did either not
include tumor-related FLAIR signal changes or regional, segmentation-based subtractions in
GB [6–8].
The aim of this study was to analyze if semi-automated volumetric assessments in GB can
predict disease progression in routine MRI follow-ups. Therefore, the change of absolute
tumor volumes (delta) and regional volume changes revealed by image subtractions were stud-
ied and compared to an expert consensus decision based on the best available data for each fol-
low-up, including histopathological results, decisions of the local multidisciplinary CNS tumor
board and neuro-radiologic reports.
Volumetric detection of glioblastoma progression
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Methods
Subjects
30 consecutive GB patients (23m, mean age 60.2y) of the local neuro-oncology clinic with at
least three high-resolution MRI follow-ups between 10/2013 and 03/2015 were included in this
single-center retrospective study. Altogether, 330 longitudinal tumor segmentations were per-
formed on high resolution 3D sequences as specified below. Diagnosis of GB was patholog-
ically confirmed in all cases at the local Department of Neuropathology. Patient records were
de-identified and analyzed anonymously.
MR imaging
High-resolution MR imaging was done on either a 3 Tesla (T) Achieva scanner (Philips Medi-
cal Systems, The Netherlands) or a 3T Verio scanner (Siemens Healthcare, Erlangen, Ger-
many) at the local Department of Neuroradiology. 3D-spoiled gradient echo sequences were
applied either with an 8-channel or 16-channel phased array head coil. T2-weighted FLAIR
sequences were acquired with a spatial resolution of 1.04 x 1.04 x 1.12 mm (TR/TE of 4800/
278, 3T Achieva) and 1 x 1 x 1 mm (TR/TE of 5000/395 ms, 3T Verio). T1-weighted magneti-
zation prepared rapid gradient echo (MPRage) sequences were acquired with a spatial resolu-
tion of 1 x 1 x 1 mm (TR/TE 9/4 ms, 3T Achieva) and 1.1 x 1.1 x 1 mm (TR/TE 1900/2.45 ms,
3T Verio). The contrast mediums Magnograf1 (MaRoTrast, Jena, Germany) or Dotarem1
(Guerbet, Villepinte, France) were administered with an automated injection system (Spectris
Solaris EP, Siemens Medical, Erlangen, Germany).
Tumor segmentation
All tumor segmentations were done semi-automatically with ‘Smartbrush’, a tool of Brainlab
Elements (Brainlab, Feldkirchen, Germany). Smartbrush is a software solution for image seg-
mentation, based on a region-growing algorithm that can be reliably used for tumor segmenta-
tions in GB [18]. Therefore a 2D-segmentation was drawn in an axial image and another 2D-
segmentation was delineated in a coronal image. These two segmentations were used to auto-
matically generate a rough 3D-interpolation of the tumor. The 3D-interpolation was then
manually corrected by adding or erasing certain areas. 165 segmentations of FLAIR images
were performed to measure the volume of FLAIR-hyperintense, tumor related changes (FV).
The corresponding 165 MPRage images were segmented in parallel to assess contrast enhanc-
ing tumor parts (CV). Structures and signal intensities that were not tumor-related, e. g micro-
angiopathy, ventricular plexus and vessels were not segmented. Further, resection cavities,
unspecific postoperative enhancement and tumor cysts were not included in the segmentation
(Fig 1) [24]. To exclude blood and postoperative blood residuals, a native MPRage sequence
and the corresponding subtraction between the contrast-enhanced MPRage and the native
MPRage sequence was displayed on a separate screen of the segmentation workstation.
Regional, segmentation-based subtractions and change of absolute
tumor volumes
We used two different methods of determining the quantifiable change between tumor volume
in two consecutive MRI scans, the regional, segmentation-based approach and the change of
absolute tumor volume. Both methods are schematically illustrated in Fig 2.
For regional, segmentation-based subtractions we registered MR images and tumor seg-
mentations (CV, FV) applying the built-in rigid image fusion tool of Brainlab based on trust
region methods [25]. Success of image registration was carefully reviewed, corrected if
Volumetric detection of glioblastoma progression
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necessary and exported to iPlan 3.0 (Brainlab, Feldkirchen, Germany). Segmentation-based
subtractions of CV and FV between two consecutive, registered MRI follow-ups were per-
formed with the logical image operation tool of iPlan 3.0 and are referred to as sCV and sFV.
Therefore a voxel-wise subtraction between the tumor segmentation of the follow-up MRI and
the baseline MRI was automatically performed by the software. Regional, segmentation based
subtractions have the advantage of still maintaining information about the voxel localization
since both images are registered (Figs 3 and 4). We further calculated the absolute change of
tumor volume between two consecutive MRI scans. Therefore we subtracted the absolute
tumor volume of the preceding MRI of the absolute tumor volume of the current MRI.
Correction for precision error
All segmentations were done by one single rater with neuro-radiologic expertise (GA) to
exclude inter-rater bias [18]. As previously described, the minimal change in volume that can
be considered ‘significant’ (least significant change, LSC) for single rater segmentations
Fig 1. Example segmentation of a complex GB. Contrast enhancing tumor volume was delineated on a
contrast enhanced MPRage image set rendering a complex tumor shape. Necrotic areas were avoided during
segmentation as it was feasible. The small spot located posterior to the segmentation on the magnified
sagittal image represents the “brush” of the semi-automated region growing tool.
doi:10.1371/journal.pone.0173112.g001
Volumetric detection of glioblastoma progression
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Fig 2. Scheme for calculations of regional, segmentation-based subtractions (sFV, upper row) and
absolute changes of tumor volume (dFV, lower row). The FLAIR segmentation of the baseline MRI is
referred to as FV1, the segmentation of the follow-up MRI as FV2. For regional, segmentation-based
subtractions (sFV) a voxel-wise subtraction was performed. Only overlapping voxels of FV1 and FV2 were
subtracted. For the absolute change of tumor volume the total change of volume between FV2 and FV1 was
calculated by subtraction.
doi:10.1371/journal.pone.0173112.g002
Fig 3. Examples of FLAIR segmentations and regional, segmentation-based subtractions. Axial FLAIR
slices of the baseline MRI (a, d) and the follow-up MRI (b, c, e, f) of a patient with GB are shown.
Segmentation of baseline FV (a, green), follow-up FV (b, blue) and an overlay image of both segmentations
(c) is presented. Baseline FLAIR image (d) and follow-up FLAIR image (e) are displayed without
segmentations. The regional, segmentation-based subtraction of FV (sFV) is also shown (f, red).
doi:10.1371/journal.pone.0173112.g003
Volumetric detection of glioblastoma progression
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between two consecutive segmentations was previously reported as 35.2% for CV segmenta-
tions and 14.4% for FLAIR segmentations using this semi-automated method [18]. We applied
a transformation and divided all delta volumes by the respective absolute LSC to get relative
‘corrected’ delta volumes. This approach was chosen since it led to a scaling of tumor volumes
making them better comparable. The corrected delta volumes are termed dCV for contrast
enhancing lesions and dFV for tumor-related FLAIR changes.
Radiologic Consensus (RC)
Neuro-radiologic reports were reviewed independently by two experienced neuroradiologists
(TH, 3 years of experience; JK, 2 years of experience) and rated on a nominal scale as follows:
0 = initial diagnosis; 1 = immediate postoperative MRI; 2 = disease regression; 3 = stable dis-
ease; 4 = uncertain disease progression (e.g. possible pseudo-progression following radiother-
apy); 5 = disease progression. Inter-rater reliability between the two raters was assessed by
Cohen’s kappa coefficient (κ) and can range between 0 (random agreement) and 1 (perfect
agreement) [26]. κ> 0.8 is termed ‘almost perfect agreement’ in this study [27]. Discrepant
ratings were reviewed in a separate session and evaluated in consensus (RC).
Fig 4. Examples of contrast-enhanced MPRage segmentations and regional, segmentation-based
subtractions. Axial MPRage slices of the baseline MRI (a, d) and the follow-up MRI (b, c, e, f) of a patient
with GB are shown. Segmentation of baseline CV (a, red), follow-up CV (b, purple) and an overlay image of
both segmentations (c) is presented. Baseline MPRage image (d) and follow-up MPRage image (e) are
displayed without segmentations. The regional, segmentation-based subtraction of CV (sCV) is also shown (f,
yellow).
doi:10.1371/journal.pone.0173112.g004
Volumetric detection of glioblastoma progression
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Multidisciplinary Consensus (MC)
For each follow-up, additional data was obtained from the clinical information system, includ-
ing histopathologic results from biopsies/resections and the decisions of the local multidisci-
plinary central nervous system (CNS) tumor board. The CNS tumor board is a weekly meeting
of neuro-oncology specialists in the field of neurology, neurosurgery, neuroradiology, neuro-
pathology, radiation oncology and nuclear medicine at our institution. Board decisions are
based on current state of the art techniques in neuro-oncology, including assessments of
RANO response criteria and results of additional positron emission tomography (PET) scans.
Each follow-up was rated on the same nominal scale as RC to obtain the best possible multidis-
ciplinary consensus. The following hierarchical steps were taken for rating of MC: Whenever
histopathologic results were available for the follow-up (16.4%) MC was accordingly rated. If
no histopathologic results were available (83.6%), MC was rated based on the decision of the
CNS tumor board (42%). For the remaining cases MC was rated similar to RC.
Generalized Linear Mixed-effects Model (GLMM)
A GLMM using a logistic link function was calculated, with MC as dependent binary variable
(progression yes / no) and delta volumes (dCV, dFV) and regional, segmentation-based sub-
tractions (sCV, sFV) as input. In addition, patient number was included as a random effect in
this model. To further compare delta volumes and regional subtractions, we generated sepa-
rate logistic mixed-effects models for both. To account for model bias, we performed 5-fold
cross-validation of both these models and DeLong’s test for correlated ROC curves using the R
package “pROC” [28]. Only cross-validated performance measures (i.e. accuracy) are reported.
We performed an exact binomial test, using the rate of progressions as per MC (i.e. the “no
information rate”) as probability of success, to assess whether the classification accuracy was
above chance.
Statistical analysis
Statistical calculations in this study were done with IBM SPSS Statistics, release 23.0 (IBM,
Armonk, NY, USA) and R version 3.3.1 (www.r-project.org). For illustrations Brainlab Ele-
ments (Brainlab, Feldkirchen, Germany), Power Point 2010 (Microsoft, Redmond, USA), R
and Adobe Photoshop CS4 (Adobe Systems, CA, USA) were used. Asterisks indicate signifi-
cant results: ‘’ P < .01, ‘’ P< .05.
Results
Median CV was 2.80 ml and median FV was 50.10 ml, the low median CV in part owing to the
effect that follow-ups immediately after tumor resections were included (Table 1). Agreement
between the two raters of the neuro-radiologic reports showed almost perfect agreement (κ =
.82, P< .001). Accordance between RC and MC was almost perfect as well (κ = .923, P<
.001), underlining a high agreement between radiologic and later multidisciplinary consensus.
RC and MC only differed in 9 follow-up evaluations. The study included 165 MR imaging
time points, leading to 135 MR follow-ups. 26 immediate postoperative MR examinations
were excluded from further GLMM analysis.
A GLMM was calculated, using MC dichotomized for ‘disease progression’ (yes / no) as
dependent variable and the following input variables: dCV, dFV, sCV and sFV. In this model,
“patient” was included as a random effect. Only dCV was significantly associated with predic-
tion of disease progression (P = .005), whereas neither dFV nor the regional, segmentation-
based subtractions showed significant effects (Table 2). To compare delta volumes and
Volumetric detection of glioblastoma progression
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Table 1. Patient characteristics and technical parameters.
Number (n), mean +/- SD or median with 25% and 75% percentile
patients (n) 30 (100%)
male / female (n) 23 / 7 (77% / 23%)
age, years (mean +/- SD) 60.2 +/- 14.99
MGMT status (n = 27)
methylated 13 (48%)
unmethylated 14 (52%)
IDH status (n = 21)
wildtype (n) 20 (95%)
mutation (n) 1 (5%)
Chemotherapy
Temozolomide (n) 26 (87%)
Bevacizumab (n) 2 (7%)
Radiotherapy
received (n) 30 (100%)
initial dose in Gy (n = 28) 60 (60–60)
MRI scans (n)
3 6
4 3
5 7
6 7
7 4
8 1
10 1
12 1
CV segmentations (n) 165
CV in ml (median) 2.80 (0.30–10.90)
dCV in ml (median) 0.00 (-2.60–3.40)
sCV in ml (median) 1.49 (0.11–6.24)
FV segmentations (n) 165
FV in ml (median) 50.10 (26.20–92.40)
dFV in ml (median) 0.80 (-16.10–19.30)
sFV in ml (median) 17.22 (7.48–35.18)
RC—MC categories
0 “initial diagnosis” (n) 6 (3.6%)–6 (3.6%)
1 “postoperative” (n) 33 (20.0%)–33 (20.0%)
2 “regression” (n) 11 (6.7%)–11 (6.7%)
3 “stable” (n) 19 (11.5%)–17 (10.3%)
4 “uncertain progression” (n) 21 (12.7%)–15 (9.1%)
5 “progression” (n) 75 (45.5%)–83 (50.3%)
SD = standard deviation, CV = contrast enhancing volume, dCV = absolute change of CV between two
consecutive MRI time points, sCV = regional, segmentation-based subtractions of CV between two
consecutive MRI time points, FV = FLAIR hyperintense volume, dFV = absolute change of FV between two
consecutive MRI time points, sFV = regional, segmentation-based subtractions of FV between two
consecutive MRI time points, RC = radiologic consensus, MC = multidisciplinary consensus.
doi:10.1371/journal.pone.0173112.t001
Volumetric detection of glioblastoma progression
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regional subtractions, we calculated separate GLMMs for both and computed the correspond-
ing ROC curves after a 5-fold cross validation (Fig 5). The cross-validated area under the curve
(AUC) of delta volumes was higher (.83) than the AUC for the volume subtractions (.75).
However, DeLong’s test did not show a significant difference between the ROC curves (P =
.162).
The GLMM for delta volumes (dCV, dFV) tended to have a higher diagnostic accuracy
(correctly classified ‘disease progression’) than the GLMM for regional, segmentation-based
subtractions (AUC: .789 [95% CI: .700–.861] versus AUC .725 [95% CI: .631–.806]). For both
models, this accuracy was above chance (assuming a no information rate of .642), although
just barely (P = .0427) in the case of the GLMM based on regional subtractions. Predicted
probabilities for disease progression showed a clearer separation when using delta volumes
compared to regional subtractions (Fig 6). However, accuracy for RC was .973 [95% CI:
.922–.994] and hence well above the volumetric parameters.
Discussion
Three main conclusions may be drawn from our study: (i) The absolute change of contrast
enhancing tumor volume is the most important volumetric determinant to detect progressive
disease. (ii) Changes in absolute tumor volume outweigh changes in regional, segmentation-
based subtractions by trend. (iii) Conventional visual evaluations of MRI images by experts are
yet more accurate than segmentation-based volumetric assessments.
Our results provide evidence that absolute volumetric changes in contrast enhancing GB
lesions between two consecutive MRI follow-ups are the main imaging determinant in tumor
volumetry for the detection of progressive disease. To minimize technical bias, we only
included 3D high-resolution imaging (both for T1 and FLAIR) and all segmentations were
done by a single rater which excludes inter-rater bias [18,29]. Further, all data were corrected
for the precision error arising from intra-rater variability [18,30,31]. Even though the precision
error for segmentations of contrast enhancement was previously reported to be more than two
times higher than for tumor-related FLAIR changes [18], the corrected change in contrast
enhancement still outweighed FLAIR changes for the prediction of progressive disease.
The current RANO criteria only suggest two-dimensional quantification of contrast
enhancing lesions, whereas FLAIR images are only qualitatively rated in RANO [2–4]. This
approach is supported by our study. Certain limitations for the assessment of contrast
enhancement apply for RANO criteria, i.e. non-measurable lesions < 10 mm in diameter or
Table 2. Results of the GLMM for dichotomized MC (‘disease progression’: Yes / No) and the follow-
ing input variables: DCV, dFV, sCV and sFV.
Estimate Std. Error P
(Intercept) -.782 .42488 .06569
dCV .40383 .14461 .00523**
dFV -.08750 .06032 .14689
sCV .21685 .11967 .06999
sFV .02769 .02171 .20227
dCV = absolute change of CV between two consecutive MRI time points, dFV = absolute change of FV
between two consecutive MRI time points, sCV = regional, segmentation-based subtractions of CV between
two consecutive MRI time points, sFV = regional, segmentation-based subtractions of FV between two
consecutive MRI time points; Asterisks indicate significant results:
** P < .01
doi:10.1371/journal.pone.0173112.t002
Volumetric detection of glioblastoma progression
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tumors around resection cavities and cysts, which cannot adequately be described by a perpen-
dicular diameter. Our generalized volumetric approach was applied at every MRI follow-up
and even small or irregular-shaped lesions could be reliably assessed. However, for the GLMM
we excluded patients with immediate post-operative MRI. Our rationale for the exclusion was
that a) postoperative signal alterations were difficult to distinguish from tumor during seg-
mentation and b) the unusual large decrease of tumor volume in immediate post-operative
MRI might have led to an overestimation of the GLMM resulting in an overly selective model
which weakens the validity for routine MRI follow-ups.
Contrast enhancement is still the best surrogate for proliferating tumor cells, however it
only reflects a disrupted blood-brain-barrier (BBB) and GB usually extends well beyond the
contrast enhancing margins [32,33]. Other causes for a disturbed BBB must be considered
when contrast enhancement is assessed, as radiotherapy, (perioperative) ischemia or novel
anti-angiogenic dugs like bevacizumab affect the BBB and subsequent MRI follow-ups [34,35].
Since we evaluated routine MRI follow-ups, the vast majority of patients have received prior
adjuvant chemo-/radiotherapies. Even though segmentations were performed with great care,
therapy-associated changes of contrast enhancement might be contained in the segmented vol-
umes. Notwithstanding this limitation, our approach showed a fair diagnostic accuracy and
can be applied at any MRI follow-up.
Fig 5. ROC-curves for volumetric determinants. Five-fold cross-validated (CV) ROC-curves for either
changes in absolute volume (delta) or regional volume subtractions (sub) for the prediction of disease
progression.
doi:10.1371/journal.pone.0173112.g005
Fig 6. Prediction probabilities for disease progression. The prediction probabilities for the binary decision
“disease progression” (yes / no) for changes in absolute volumes (left) and regional subtractions (right). Note
that while the boxes in Fig 6 (left) do not overlap, this is the case in Fig 6 (right), indicating that a model based
on delta volumes better separates progressive from non-progressive follow-up examinations.
doi:10.1371/journal.pone.0173112.g006
Volumetric detection of glioblastoma progression
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Progressive FLAIR changes are only qualitatively included in the current RANO criteria
[4]. As opposed to contrast enhancement, RANO only requires a “significant” increase in
FLAIR signal to establish disease progression. Further complicating FLAIR assessment beyond
this subjective criterion, several competing causes for FLAIR signal increase like radiation
therapy, ischemia, seizures, decreasing doses of corticosteroids, postoperative changes or other
treatment effects must be taken in consideration when evaluating FLAIR images [4, 36]. Even
though previous studies suggested cut-offs for progressive FLAIR changes [37], our study did
not establish a significant association of changes in FLAIR signal with prediction of disease
progression. As we performed volumetric assessments in every consecutive MRI, the above
mentioned exceptions for FLAIR progression in RANO apply as limitations to our approach.
However, our method aimed to simplify quantitative assessments in routine MRI follow-ups
without having too many exceptions or non-measurable cases.
Regional, segmentation-based volume subtractions performed on registered MR images
did not provide an advantage compared to absolute changes in volume. There are two main
explanations that should be considered. First, local inaccuracies during semi-automated seg-
mentations might account for regional subtraction errors, even though segmentations were
done with great care. Second, regional volume subtractions largely depend on the quality of
image registration, which is an important and well-studied field in imaging [25,38–41]. How-
ever image registration has certain limitations when applied to postoperative MRI since the
resection cavity, brain shift or signal changes due to edema, ischemia or bleeding complicate
its applicability. Rigid registration techniques are prone to misregistration at the resection
margins in postoperative MRI. Even though we excluded immediate postoperative MRI,
(small) registration errors might explain the weak performance of regional subtractions in this
study since progressive disease usually occurs at the resection margins. Ideally non-rigid
image registration techniques should be applied and further developed [38,40]. However,
these techniques sometimes apply spatial transformations of MR images which could lead to
inaccurate tumor volumes [41]. Despite these limitations, human raters might still benefit
from regional subtractions since local changes can be easily visualized and evaluated.
Previous authors reported good correlations between established one- or two-dimensional
assessments and novel three-dimensional volumetry in GB raising the question of its addi-
tional value [9–12]. Semi-automated or manual segmentations require more time and the
development and implementation of appropriate software solutions, which can limit the
usability and availability in routine clinical evaluation of follow-up MRIs. Nevertheless, auto-
mated segmentation techniques are being developed which can save time and exclude human
bias [5,16]. Further, it is likely that automated segmentations might get integrated in the pic-
ture archiving and communication system (PACS), making them more available. In the future,
volumetric assessments might be part of novel objective response criteria since their use in cur-
rent clinical trials is already increasing [6–8]. However, sole volumetric assessments are still
outperformed by experienced human raters. Current volumetric assessments in GB might
therefore primarily assist professional human raters in routine MR follow-up examinations.
Assessing an additional diagnostic benefit would require very large cohorts since agreement
between conventional radiologic consensus and multidisciplinary consensus was high in our
study.
Besides the usual limitations of a retrospective study design some further restrictions should
be considered when interpreting the results in this study. The dependent binary variable MC
in the GLMM was evaluated to the best of our knowledge, taking histologic results and consen-
sus decisions of the CNS tumor board based on RANO criteria into account. Though, in
almost half of all cases the radiologic consensus decision was the only available variable to rate
MC. Second, we intended to quantify tumor volumes in all follow-ups. Therefore, therapy-
Volumetric detection of glioblastoma progression
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related changes due to adjuvant radio- and chemotherapies are present in some MR images
and could not be distinguished from tumor volumes during segmentations in a few cases.
Third, even small contrast enhancing lesions were included in the segmentations since 3D-
high-resolution MRI data was used. However, in some cases minor signal alterations, i.e.
enhancement at the rim of the resection cavity, could not be reliably distinguished from post-
operative scaring or unspecific enhancement. In particular, small segmentations were prone to
wrong registration in image fusion and might lead to higher results in image subtractions due
to the absence of overlapping regions.
Conclusion
In longitudinal MRI follow-ups of glioblastoma, the change in absolute volume of contrast
enhancement is the most important volumetric parameter to detect progressive disease and is
an objective imaging determinant. Regional, segmentation-based image subtractions are less
reliable by trend, probably because of local inaccuracies of current image segmentation and
registration techniques. Conventional visual evaluation of imaging experts is yet more accurate
than volumetric assessments in MRI follow-ups of glioblastoma.
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